Core Insights - Coloplast is restructuring its Executive Leadership Team (ELT) to align with its new strategy aimed at enhancing customer experience and innovation [1][2][3] - The new strategy emphasizes placing customers at the center of operations and aims to set industry standards while leading the market [2][3] Business Structure Changes - Coloplast has established two distinct business units: Chronic Care and Acute Care, to better address market dynamics and customer needs [4] - A new Chronic Care Commercial business unit has been created, incorporating existing sales regions and functions, including Atos Medical's Voice & Respiratory Care [5] - A stand-alone Chronic Care R&D function is being set up to accelerate product innovation and market delivery [6] Leadership Changes - Nicolai Buhl, Executive Vice President, will leave Coloplast as part of the restructuring, with Caroline Vagner Rosenstand appointed as the new Executive Vice President of Chronic Care Commercial [7][8] - Rasmus Just will assume the role of Executive Vice President of Chronic Care R&D starting November 1, bringing experience from both Coloplast and Novo Nordisk [8][9] Acute Care Unit Introduction - The Acute Care business unit will include Interventional Urology, Advanced Wound Dressings, and Kerecis, focusing on premium products used in specialized clinics and hospitals [10] - The commercial organizations of Advanced Wound Dressings and Kerecis are merging into a new Wound & Tissue Repair organization, led by Fertram Sigurjonsson [11][12] New Executive Leadership Team - The new ELT includes Lars Rasmussen as interim CEO and Anders Lonning-Skovgaard as CFO, along with other key executives overseeing various business units [15][19]